Scientists are increasingly using metabolomics together with other omics tools to better inform and enable critical decision-making across the various phases of the drug discovery and development process1.
Experts will discuss how the integration of metabolomics with other omics data streams enables R&D programs to:
1. Richard D. Beger, et. al. Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine. Metabolites. 27 March 2020
Dr. Lotta, MD, Ph.D., joined the Regeneron Genetics Center in 2019 as head of cardiovascular, metabolic and musculoskeletal translational genetics, focusing on therapeutic target identification and validation using large scale human genetics and health data. He’s a physician scientist and clinical epidemiologist by training having completed his MD at the University of Milan (Italy) and his Ph.D. studies in Methodology of Clinical Research and Clinical Epidemiology at the University of Milan and the University of Leiden (The Netherlands). Before joining the RGC, Luca was a Senior Clinical Investigator in the MRC Epidemiology Unit and Institute of Metabolic Science at the University of Cambridge (UK), an Honorary Clinical Fellow at Addenbrooke’s Hospital and a Fellow of the Governing Body of Wolfson College Cambridge.
Dr. Beger, Ph.D., has led NCTR in metabolomics, lipidomics, proteomics and tissue imaging efforts in system biology and precision medicine studies for the past 20 years. As a Branch Chief, he has helped plan the studies, analyze data, interpret findings, write manuscripts, and present data at many national and international conferences. Richard has been involved with omics biomarker research collaborations with scientists at many FDA Centers including CDER, academia, and industry scientists. He primarily works in discovering translational metabolomics and proteomics biomarkers of hepatoxicity, cardiotoxicity, neurotoxicity, nephrotoxicity, developmental toxicity, disease status, and toxicity susceptibility. Richard won the 2016 SOT translational impact award for developing translational approaches to improve drug safety, disease detection/management, and human health.
Dr. Sarangarajan, Ph.D., is a recognized R&D leader, driving the course for multi-functional teams integrating biology, technology, and artificial intelligence analytics in the development of a multi-omics, biology-based platforms for the discovery of disease-specific targets, therapeutic discovery, and diagnostics development. He previously served as Chief Scientific Officer and SVP Clinical and Translational Sciences at BERG where he was focused on integration and use of multi-omics data driven target identification/validation and drug discovery/clinical development. Ranga obtained his Ph.D. in Pharmaceutical Sciences from the University of Cincinnati and a B.S. in Pharmacy from Maharaja Sayajirao University.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.